Ge Zhang, PhD

Ge Zhang, PhD has a diverse work experience in the fields of scientific strategy, innovation, consulting, and business development. They are currently serving as the Associate Director of Scientific Strategy and Innovation at Entrada Therapeutics since June 2022. Prior to this role, they worked as the Senior Manager of Scientific Strategy and Innovation at the same company from September 2021 until June 2022.

Before joining Entrada Therapeutics, Ge Zhang worked as a Consultant at Axiom Healthcare Strategies from August 2020 to September 2021. In this role, they focused on topics such as multiple myeloma, non-small cell lung cancer, and precision medicine. Their responsibilities included strategy development, competitive intelligence analysis, and coverage of medical conferences.

Prior to Axiom Healthcare Strategies, Ge Zhang served as a Consultant at Boston Consulting Group (BCG) from February 2019 to August 2020. They worked on various strategy projects across different industries, with a particular focus on healthcare, including the MedTech and Biopharma sectors. They also contributed to business development efforts during their time at BCG.

In 2016, Ge Zhang worked as a Business Development Fellow at the Harvard Office of Technology Development. This role focused on identifying and evaluating commercialization opportunities for technology developed at Harvard University.

Ge Zhang started their career as a Research Assistant at the University of North Carolina at Chapel Hill from September 2009 to May 2012. In this role, they conducted research in an academic setting.

Overall, Ge Zhang has a strong background in scientific strategy, innovation, consulting, and business development, with experience in both industry and academic settings.

Ge Zhang, PhD, attended the University of North Carolina at Chapel Hill from 2008 to 2012, where they earned a Bachelor of Science (B.S.) degree in Chemistry. Following their undergraduate studies, Zhang pursued further academic advancement at Harvard University from 2012 to 2018. During this period, they successfully completed their doctoral studies and obtained a Doctor of Philosophy (PhD) degree in Chemistry.